DrugDev Launches Clinical Site Activation SaaS Technology as Key Part of Its Unified Platform to Reduce the Time of Startup from Months to Weeks

Share Article

Technology based on years of proven best practices for clinical trial agreement (CTA) negotiations, budget development and the collection of essential regulatory documents.

The DrugDev site activation module can reduce clinical trial startup time from months to weeks

Melissa (Liss) Easy, DrugDev Founder and President of Site Startup: The whole point is finding the right site, getting them activated, and setting them up for success as quickly as possible.

DrugDev continues to add innovative technology features to its award-winning platform for clinical trial optimization with its new site activation module, which can reduce startup time from months to weeks. Based upon years of proven best practices of helping leading sponsors and CROs shave months off the startup process, DrugDev’s site activation technology - now available to customers directly as a SaaS solution in addition to traditional outsourcing - enables companies to enhance efficiency, improve site relationships and reduce the time spent on startup activities by at least 20%.

DrugDev will officially launch the new technology at the SCOPE Summit for Clinical Ops Executives in Miami, February 22-25. Join a complimentary webinar to view the system in action on March 17, 2016 at 12pm ET. Register here.

DrugDev technology supports collaboration between sponsors, CROs and sites by providing complete transparency into the real-time status for clinical trial agreement (CTA) negotiations, budget development and essential regulatory document collection. The system features an intuitive interface with single sign-in that guides users to complete outstanding actions, visual real-time progress dashboard reports, and unification throughout the DrugDev platform for learning management, site engagement and study workflow optimization.

Customers receive additional value by integrating the DrugDev Golden Number, a universal identifier that powers the revolutionary TransCelerate Investigator Registry and the Investigator Databank collaborations, throughout the site activation process. The Golden Number can be implemented for site activation as well as in other clinical systems (e.g. site selection, DrugDev Payments, EDC, CTMS) to create master profiles for sites and investigators around the world.

CTAs are further simplified by leveraging prior existing contract language (where available) to streamline negotiations and ensure consistency of terms, while the ease of collecting and maintaining regulatory documents delivers a painless process that eliminates site frustration and removes a significant barrier to trial participation.

Ibraheem (Ibs) Mahmood, President and CEO of DrugDev, said, “We’ve been working with customers for years to transform what is otherwise a very frustrating and time-consuming process, which often generates friction with sites, into an efficient and transparent collaboration that wraps up in a few weeks rather than dragging on for several months. To be honest, I feel a bit guilty for having kept this technology to ourselves for so long, so I’m relieved and excited we are finally making it available directly to sponsors and CROs. As would be expected, the module is integrated into our award-winning platform and leverages the DrugDev Golden Number to ensure overall clinical operations success for our valued customers.”

Melissa (Liss) Easy, DrugDev Founder and President of Site Startup, explained, “The best part of delivering our activation technology as a SaaS solution is the flexibility and choice it provides. Every trial is different, so sponsors and CROs who want to streamline the startup process may elect to outsource responsibility to our expert team, use our technology themselves, have a CRO partner use it, or engage in a hybrid that combines the models. The whole point is finding the right site, getting them activated, and setting them up for success as quickly as possible. By combining the DrugDev platform, the DrugDev Golden Number and our global network of investigators, customers will identify ideal investigators, execute CTAs, collect essential site regulatory documents, and activate trials faster than anyone thought possible.”

To learn how DrugDev enables the world to do more trials through industry-wide collaboration, standardization and a beautiful technology experience, begin a conversation at drugdev.com.

About DrugDev
DrugDev’s unified platform enables sponsors, CROs and sites to do more trials through industry-wide collaboration, standardization and a beautiful technology experience. Featuring solutions for global site payments, site identification and activation, workflow optimization, learning management, and site and patient engagement, DrugDev helps companies transform the quality and efficiency of clinical trials from startup through closeout. The company also powers the revolutionary TransCelerate Investigator Registry and Investigator Databank collaborations with the universal identifier known as the DrugDev Golden Number. Learn why 9 of the top 10 sponsors, and 4 of the top 5 CROs trust DrugDev technology at drugdev.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brenda Nashawaty
DrugDev
+1 617-688-3253
Email >

Cindy Murray
DrugDev
1-888-650-1860
Email >
Visit website